Top

Annals of Hematology

Published in:

01-03-2017 | Letter to the Editor

Radiologic and molecular remission of follicular T cell lymphoma treated with lenalidomide

Author: Yok-Lam Kwong

Published in: Annals of Hematology | Issue 3/2017

Excerpt

Dear Editor, …

Huang Y, Moreau A, Dupuis J, Streubel B, Petit B, Le Gouill S, Martin-Garcia N, Copie-Bergman C, Gaillard F, Qubaja M, Fabiani B, Roncador G, Haioun C, Delfau-Larue MH, Marafioti T, Chott A, Gaulard P (2009) Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. Am J Surg Pathol 33(5):682–690CrossRefPubMedPubMedCentral

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390CrossRefPubMed

Rüdiger T, Ichinohasama R, Ott MM, Müller-Deubert S, Miura I, Ott G, Müller-Hermelink HK (2000) Peripheral T-cell lymphoma with distinct perifollicular growth pattern: a distinct subtype of T-cell lymphoma? Am J Surg Pathol 24(1):117–122CrossRefPubMed

de Leval L, Savilo E, Longtine J, Ferry JA, Harris NL (2001) Peripheral T-cell lymphoma with follicular involvement and a CD4+/bcl-6+ phenotype. Am J Surg Pathol 25(3):395–400CrossRefPubMed

Ikonomou IM, Tierens A, Troen G, Aamot HV, Heim S, Lauritzsen GF, Vålerhaugen H, Delabie J (2006) Peripheral T-cell lymphoma with involvement of the expanded mantle zone. Virchows Arch 449(1):78–87CrossRefPubMed

Moroch J, Copie-Bergman C, de Leval L, Plonquet A, Martin-Garcia N, Delfau-Larue MH, Molinier-Frenkel V, Belhadj K, Haioun C, Audouin J, Swerdlow SH, Marafioti T, Gaulard P (2012) Follicular peripheral T-cell lymphoma expands the spectrum of classical Hodgkin lymphoma mimics. Am J Surg Pathol 36(11):1636–1646CrossRefPubMed

Au WY, Pang A, Choy C, Chim CS, Kwong YL (2004) Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 104(1):243–249CrossRefPubMed

Dueck G, Chua N, Prasad A, Finch D, Stewart D, White D, van der Jagt R, Johnston J, Belch A, Reiman T (2010) Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 116(19):4541–4548CrossRefPubMed

Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, Glaisner S, Gabarre J, Bosly A, Lister J, Li J, Coiffier B (2013) A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer 49(13):2869–2876CrossRefPubMed

10.

Toumishey E, Prasad A, Dueck G, Chua N, Finch D, Johnston J, van der Jagt R, Stewart D, White D, Belch A, Reiman T (2015) Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer 121(5):716–723CrossRefPubMed

11.

Querfeld C, Rosen ST, Guitart J, Duvic M, Kim YH, Dusza SW, Kuzel TM (2014) Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. Blood 123(8):1159–1166CrossRefPubMed

12.

Kritharis A, Coyle M, Sharma J, Evens AM (2015) Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities. Blood 125(16):2471–2476CrossRefPubMedPubMedCentral

13.

Vallois D, Dobay MP, Morin RD, Lemonnier F, Missiaglia E, Juilland M, Iwaszkiewicz J, Fataccioli V, Bisig B, Roberti A, Grewal J, Bruneau J, Fabiani B, Martin A, Bonnet C, Michielin O, Jais JP, Figeac M, Bernard OA, Delorenzi M, Haioun C, Tournilhac O, Thome M, Gascoyne RD, Gaulard P, de Leval L (2016) Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood 128(11):1490–1502CrossRefPubMed

14.

Kurita D, Miyoshi H, Yoshida N, Sasaki Y, Kato S, Niino D, Sugita Y, Hatta Y, Takei M, Makishima M, Ohshima K (2016) A clinicopathologic study of Lennert lymphoma and possible prognostic factors: the importance of follicular helper T-cell markers and the association with angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 40(9):1249–1260CrossRefPubMed

Title: Radiologic and molecular remission of follicular T cell lymphoma treated with lenalidomide
Author: Yok-Lam Kwong
Publication date: 01-03-2017
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 3/2017
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-016-2873-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Radiologic and molecular remission of follicular T cell lymphoma treated with lenalidomide

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2017

Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8

Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center

GM-CSF treatment is not effective in congenital neutropenia patients due to its inability to activate NAMPT signaling

Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004–2013

Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic

JAK2V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohort

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page